Tithon Biotech
Tithon Biotech is a biotechnology company dedicated to developing biomedical solutions for degenerative medical conditions affecting humans and animals. With a focus on regenerative medicine and stem cell technology, the company aims to improve life through bioscience by pioneering advanced discoveries and innovative therapies.
Industries
Nr. of Employees
small (1-50)
Tithon Biotech
11440 West Bernardo Court, Suite 300, San Diego, CA, 92127, USA
Patents
Products
Sealed peripheral blood-derived pluripotent stem cell (PBD-PSC) kits
Kits containing components necessary for medical providers to perform autologous, minimally-manipulated regenerative procedures in a clinic setting.
Alginate cross-linking biomaterials and encapsulation processes
A novel alginate cross-linking method with improved bonding strength and antimicrobial properties intended for medical uses (wound dressings, scaffolds, encapsulation) and non-medical applications (yeast encapsulation for beverages and ethanol production).
Organ tissue buds (R&D project)
In‑vitro generated 3D organ tissue buds derived from peripheral blood-derived pluripotent cells intended as laboratory research supply and a pathway toward vascularized organ regeneration (kidney, pancreas, intestine, heart, lung, brain).
Therapeutic peptide derived from stem cell secretome (Ad-813)
A bioactive peptide identified from stem cell secretome proteomic analysis, developed for indications such as wound healing and pain suppression with efforts toward oral formulation.
Sealed peripheral blood-derived pluripotent stem cell (PBD-PSC) kits
Kits containing components necessary for medical providers to perform autologous, minimally-manipulated regenerative procedures in a clinic setting.
Alginate cross-linking biomaterials and encapsulation processes
A novel alginate cross-linking method with improved bonding strength and antimicrobial properties intended for medical uses (wound dressings, scaffolds, encapsulation) and non-medical applications (yeast encapsulation for beverages and ethanol production).
Organ tissue buds (R&D project)
In‑vitro generated 3D organ tissue buds derived from peripheral blood-derived pluripotent cells intended as laboratory research supply and a pathway toward vascularized organ regeneration (kidney, pancreas, intestine, heart, lung, brain).
Therapeutic peptide derived from stem cell secretome (Ad-813)
A bioactive peptide identified from stem cell secretome proteomic analysis, developed for indications such as wound healing and pain suppression with efforts toward oral formulation.
Services
Planned operation of clinics to provide diagnostic and therapeutic regenerative procedures using peripheral blood-derived pluripotent cell technology.
Planned operation of clinics to provide diagnostic and therapeutic regenerative procedures using peripheral blood-derived pluripotent cell technology.
Expertise Areas
- Peripheral blood-derived pluripotent stem cell isolation and banking
- Directed differentiation and lineage programming
- Organoid culture and disease modeling
- Autologous cell therapy development and local engraftment
Key Technologies
- Peripheral blood-derived pluripotent stem cells
- Antibody-based positive selection
- Organoid culture systems
- Directed differentiation protocols
News & Updates
Tithon Biotech, Inc is pleased to announce that Dr. Charles Mahl, has joined Tithon’s Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon Scientific and Medical Advisory Board provides professional knowledge, expertise and experience to guide the growth and development of Tithon in its pursuit of Improving Life.
Tithon Biotech, Inc. is pleased to announce that Mr. Greg King, has joined Tithon Biotech, Inc., as its Chief Executive Officer. Dr. Vasilis (“Bill”) Paspaliaris, Tithon’s founder and Chairman, commented: “On behalf of the board of directors, I would like to welcome Greg and express my full faith and confidence in his ability to guide Tithon as its Chief Executive Officer.”
Tithon Biotech, Inc is pleased to announce that Dr. Terry Grossman, a pioneer in the field of nutritional medicine and longevity has joined Tithon’s Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon Scientific and Medical Advisory Board provides professional knowledge, expertise and experience to guide the growth of the company.
Thank you to all who attended the First Symposium for the AABRM in Kuala Lumpur 17-18 December 2016, proudly sponsored by Tithon Biotech, Inc. Please see the below video which summarizes the event.
Tithon Biotech, Inc is pleased to announce that Dr. Charles Mahl, has joined Tithon’s Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon Scientific and Medical Advisory Board provides professional knowledge, expertise and experience to guide the growth and development of Tithon in its pursuit of Improving Life.
Tithon Biotech, Inc. is pleased to announce that Mr. Greg King, has joined Tithon Biotech, Inc., as its Chief Executive Officer. Dr. Vasilis (“Bill”) Paspaliaris, Tithon’s founder and Chairman, commented: “On behalf of the board of directors, I would like to welcome Greg and express my full faith and confidence in his ability to guide Tithon as its Chief Executive Officer.”
Tithon Biotech, Inc is pleased to announce that Dr. Terry Grossman, a pioneer in the field of nutritional medicine and longevity has joined Tithon’s Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon Scientific and Medical Advisory Board provides professional knowledge, expertise and experience to guide the growth of the company.
Thank you to all who attended the First Symposium for the AABRM in Kuala Lumpur 17-18 December 2016, proudly sponsored by Tithon Biotech, Inc. Please see the below video which summarizes the event.